A Boost for Access, Lower Costs, and a Push to Increase Vaccination Rates

China's new domestically-produced 9-valent HPV vaccine is expected to increase access to the cancer-preventing shot. This makes China the second country, after the US, to independently produce this high-valence vaccine.

Xiamen Innovax Biotech's new vaccine has been approved. Currently, China offers bivalent, quadrivalent, and 9-valent HPV vaccines. The 9-valent version was previously only made by Merck & Co. The new vaccine has slightly different dosage requirements, potentially reducing costs for some.

While the new vaccine's price is not yet public, cities are offering discounts on the imported vaccine in anticipation of increased supply. The imported vaccine is in short supply. Experts believe the new domestic vaccines will boost supply and improve access.

Vaccination rates in China are relatively low, but increasing. Low uptake is due to limited access and awareness. Early immunization is important, as younger girls produce stronger immune responses.

Public awareness has grown, potentially boosting vaccine acceptance. The HPV vaccine has high value in health economics. Growing policy support and market enthusiasm are creating favorable conditions. The 9-valent vaccine offers greater protection than the quadrivalent. Many regions are launching free or subsidized vaccination programs.